aromatase inhibitor anastrozole oncology
Selected indexed studies
- Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. (Ann Oncol, 2024) [PMID:38729566]
- A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial. (Ann Oncol, 2025) [PMID:39442617]
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. (J Clin Oncol, 2017) [PMID:28968163]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Anastrozole. (2010) pubmed
- Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. (2024) pubmed
- Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. (2005) pubmed
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. (2017) pubmed
- A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial. (2025) pubmed
- Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial. (2025) pubmed
- Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2. (2019) pubmed
- Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+/HER2- advanced breast cancer: Final results of the randomized phase III MONARCH plus trial. (2025) pubmed
- Anastrozole: a new selective nonsteroidal aromatase inhibitor. (1997) pubmed
- Anastrozole: a selective aromatase inhibitor for the treatment of breast cancer. (1998) pubmed